Cachexia‐induced reprogramming of visceral organ metabolism by human pancreatic cancer xenografts
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35487 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Raj Kumar Sharma und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cachexia, Pancreatic Neoplasms, Viscera. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Pancreatic cancer patients with cachexia experience functional changes in visceral organs. To further understand these functional changes, here, for the first time, we characterized metabolic changes in the spleen, liver, pancreas, lungs, heart, and kidneys induced by human pancreatic cancer xenografts. These studies identify the commonality and consequences of cachexia‐induced visceral organ metabolic dysregulation. The heart, kidneys, liver, lungs, pancreas, and spleen from euthanized non‐tumor‐bearing control mice and from cachexia‐inducing Pa04C and non‐cachexia‐inducing Panc1 tumor‐bearing mice ( n = 8–10 per group) were metabolically characterized with 1H magnetic resonance spectroscopy. All visceral organs, with the exception of lungs, exhibited significant weight reduction in cachectic Pa04C mice relative to normal and non‐cachectic Panc1 mice. A significant reduction ( p ≤ .0166) of organ metabolites ranging from the amino acids leucine, isoleucine, valine, alanine, lysine, arginine, asparagine, glutamate, glutamine, aspartate, glycine, tyrosine, and phenylalanine, along with glucose, lactate, creatine, choline, and fumarate, depending upon the visceral organ, was observed in cachectic Pa04C mice compared to normal mice. The highest number of metabolites was reduced in the spleen, followed by the kidneys, lungs, and liver. The metabolic changes identified can lead to negative consequences in organ function by impacting pathways involved in tissue regeneration and resolving inflammation at the cellular level in cachectic mice. These results highlight the visceral organ metabolic reprogramming that can occur with cancer‐induced cachexia, an understanding of which can identify noninvasive biomarkers and metabolic interventions to reduce morbidity and mortality from pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Raj Kumar Sharma
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sharma, R. K., Winnard, P. T., Bharti, S. K., Krishnamachary, B., Mironchik, Y., Penet, M. F., & Bhujwalla, Z. M. (2025). Cachexia‐induced reprogramming of visceral organ metabolism by human pancreatic cancer xenografts. International Journal of Cancer. https://doi.org/10.1002/ijc.35487
Vancouver
Sharma RK, Winnard PT, Bharti SK, Krishnamachary B, Mironchik Y, Penet MF, et al. Cachexia‐induced reprogramming of visceral organ metabolism by human pancreatic cancer xenografts. International Journal of Cancer. 2025. doi:10.1002/ijc.35487
BibTeX
@article{Sharma2025,
author = {Sharma, Raj Kumar and Winnard, Paul T and Bharti, Santosh Kumar and Krishnamachary, Balaji and Mironchik, Yelena and Penet, Marie-France and Bhujwalla, Zaver M},
title = {Cachexia‐induced reprogramming of visceral organ metabolism by human pancreatic cancer xenografts},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35487}
}
EUVIMED